$ALXN News
Last published 2mo ago
- 2mo agoGOOGLALXNClearlake Capital and Google Cloud Form Strategic Partnership to Deliver Full-Stack Enterprise AI Across Portfolio CompaniesGoogle Cloud Press Corner
- 2mo agoGOOGLALXNClearlake Capital and Google Cloud Form Strategic Partnership to Deliver Full-Stack Enterprise AI Across Portfolio CompaniesGoogle Cloud Press Corner
- 1y agoIMCRALXNResolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business OfficerPR NewswireResolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage...
- 1y agoALXNApproval of Voydeya, Nda #218037 (REMS)FDA Approved DrugsApproval Date: 06/30/2025; Drug Name: Voydeya, Nda #218037; Active Ingredients: DANICOPAN; Company: Alexion Pharms Inc; Submission Status: Approval; Submission Classification: REMS; Application Number: 218037
- 2y agoALXNAlexion Pharmaceuticals, Inc. et al. vs Samsung Bioepis Co., Ltd. - AIA Trial, Settled After InstitutionUS Patent Trial and Appeal Board
- 2y agoALXNAlexion Pharmaceuticals, Inc. et al. vs Samsung Bioepis Co., Ltd. - AIA Trial, Settled After InstitutionUS Patent Trial and Appeal Board
- 2y agoALXNAlexion Pharmaceuticals, Inc. et al. vs Samsung Bioepis Co., Ltd. - AIA Trial, Settled After InstitutionUS Patent Trial and Appeal Board
- 2y agoALXNAlexion Pharmaceuticals, Inc. et al. vs Samsung Bioepis Co., Ltd. - AIA Trial, Settled After InstitutionUS Patent Trial and Appeal Board
- 2y agoALXNAlexion Pharmaceuticals, Inc. et al. vs Samsung Bioepis Co., Ltd. - AIA Trial, Settled After InstitutionUS Patent Trial and Appeal Board
- 2y agoALXNA Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults - NCT06173596ClinicalTrials.govMaximum Observed Plasma Concentration (Cmax) of ALXN2080, Area Under the Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-last) of ALXN2080, Cmax of Itraconazole, (and 6 more...)
- 3y agoALXNSEC Charges Police Chief, Four Others in Connection with Insider Trading Before Pharmaceutical MergerSEC Press ReleasesThe Securities and Exchange Commission today filed insider trading charges against five individuals, including a police chief in Dighton, Massachusetts, arising from trading before the announcement of a tender offer by Alexion Pharmaceuticals Inc. to…
- 3y agoALXNAZNEculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China - NCT05876351ClinicalTrials.govNumber of Participants Considered as Complete Thrombotic Microangiopathy (TMA) Responders, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Pharmacokinetics (PK): Serum Eculizumab Concentration, (and 8 more...)
- 3y agoALXNA Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants - NCT05780645ClinicalTrials.govMaximum Observed Plasma Concentration (Cmax) of ALXN2050, Time to Reach Cmax (Tmax) of ALXN2050, Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of Last Measurable Concentration (AUC0-last) of ALXN2050, Number of Participants With Adverse Events (AEs)
- 3y agoALXNSafety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants - NCT05751642ClinicalTrials.govNumber of participants with Adverse events (AEs), Maximum observed concentration (Cmax), Time to maximum observed concentration (tmax), (and 15 more...)
- 3y agoALXNARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE - NCT05746559ClinicalTrials.govNumber of Participants Experiencing Major Adverse Kidney Events (MAKE) (Based on serum Cystatin C [sCysC]) at Day 90 Post Cardiopulmonary Bypass (CPB), Number of Participants Free From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) at Day 90 Post CPB, Number of Participants Free From Severe CSA-AKI (Kidney Disease: Improving Global Outcomes [KDIGO] Stage 2 or 3) Based on Highest Observed ...
- 3y agoALXNPotential Drug Interaction Between ALXN2040 and Rosuvastatin - NCT05708573ClinicalTrials.govMaximum observed plasma drug concentration during a dosing interval (Cmax) of rosuvastatin, Area under the concentration-time curve from time zero to the time of the last observed/measured nonzero concentration (AUC0-last) of rosuvastatin, Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of rosuvastatin, (and 9 more...)
- 3y agoALXNEarly Access Program for ALXN1840 in Patients With Wilson Disease - NCT05686564ClinicalTrials.gov
- 3y agoALXNEvaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) - NCT05644561ClinicalTrials.govPlasma Concentration of Ravulizumab, Serum Free C5 Concentration of Ravulizumab, Change From Baseline in The Quantitative Myasthenia Gravis (QMG) Total Score at Up to Week 18, (and 11 more...)
- 3y agoALXNPharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants - NCT05641311ClinicalTrials.govArea Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) Of Plasma Total Molybdenum After Each Dose
- 4y agoALXNBioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics - NCT05578846ClinicalTrials.govCmax (Maximum observed plasma (peak) concentration of the drug), AUCt (Area under the concentration time curve from time zero to the last quantifiable concentration), AUC∞ (Area under the concentration time curve from time zero extrapolated to infinity), (and 7 more...)
- 4y agoALXNSafety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis - NCT05556096ClinicalTrials.govChange From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26, Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26, Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26, (and 2 more...)
- 4y agoALXNSafety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants - NCT05501717ClinicalTrials.govNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), Maximum Observed Plasma Concentration (Cmax), Time to Maximum Observed Plasma Concentration (Tmax), (and 4 more...)
- 4y agoALXNSafety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants - NCT05428696ClinicalTrials.govNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) Of Single Dose ALXN2080, Maximum Observed Plasma Concentration (Cmax) of Single Dose ALXN2080
- 4y agoALXNLysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease - NCT05419765ClinicalTrials.govLAL activity, LAL activity variation
- 4y agoALXNScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program - NCT05368038ClinicalTrials.govEvaluate the accuracy of the screening assays., Define disease incidence in an ethnically diverse population.
- 4y agoALXNA Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults - NCT05319912ClinicalTrials.govArea Under The Concentration Versus Time Curve To The Last Measurable Concentration (AUC0-t) Of Total Molybdenum, Maximum Measured Plasma Concentration (Cmax) Of Total Molybdenum, Count Of Participants Experiencing Treatment-emergent Adverse Events
- 4y agoALXNA Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults - NCT05319899ClinicalTrials.govArea Under The Concentration Versus Time Curve To The Last Measurable Concentration (AUC0-t) Of Total Molybdenum, Maximum Measured Plasma Concentration (Cmax) Of Total Molybdenum, Count Of Participants Experiencing Treatment-emergent Adverse Events
- 4y agoALXNSafety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria - NCT05314231ClinicalTrials.govSerum Concentration of ALXN1720, Number of Participants With Treatment-Emergent Adverse Events, Serum Concentration of Free and Total Complement Component 5 (C5), Number of Participants With Antidrug Antibodies (ADAs) to ALXN1720
- 4y agoALXNSafety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants - NCT05307978ClinicalTrials.govNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), Maximum Observed Serum Concentration (Cmax), Time to Maximum Observed Serum Concentration (Tmax), (and 4 more...)
- 4y agoALXNA Study of Multiple Doses of ALXN1210 in Healthy Adult Participants - NCT05288673ClinicalTrials.govParticipants With Treatment-Emergent Adverse Events, Area Under The Concentration-time Curve From Time 0 (Dosing) To Infinity (AUCinf) Of Serum ALXN1210, AUC From Time Zero To The Time Of The Last Quantifiable Concentration (AUCt) Of Serum ALXN1210, (and 6 more...)
- 4y agoALXNA Study of a Single Dose of ALXN1210 in Healthy Participants - NCT05288660ClinicalTrials.govIncidence Of Treatment-Emergent AEs, Maximum Observed Serum Concentration (Cmax) Of Serum ALXN1210, Time To Maximum Observed Serum Concentration (Tmax) Of Serum ALXN1210, (and 13 more...)
- 4y agoALXNA Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants - NCT05288816ClinicalTrials.govIncidence Of Treatment-Emergent Adverse Events, Incidence Of Anti-Drug Antibodies (ADAs) To ALXN1210, Area Under The Concentration-Time Curve From Time Zero To Infinity (AUCinf) For Single And Multiple Doses Of ALXN1210, (and 4 more...)
- 4y agoALXNA Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants - NCT05288829ClinicalTrials.govIncidence Of Treatment-Emergent Adverse Events, Absolute Bioavailability Of ALXN1210 SC, Percent Change From Baseline In Free Complement Component 5 (C5) At Day 8, (and 2 more...)
- 4y agoALXNReal Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria - NCT05274633ClinicalTrials.govPercentage Change In Lactate Dehydrogenase (LDH) From Baseline To End Of Observation, Percentage Change In LDH From Baseline To End Of Observation On Participants Treated With Ravulizumab With Respect To The Observed Treatment Period With Eculizumab, Number of Transfusions During Treatment Period With Ravulizumab, (and 9 more...)
- 4y agoALXNStudy of ALXN2050 in Participants With Hepatic Impairment - NCT05259085ClinicalTrials.govArea Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state, Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state, Maximum (Peak) Steady-state Plasma Concentration Of ALXN2050 (Cmax,ss), (and 2 more...)
- 4y agoALXNA Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants - NCT05254613ClinicalTrials.govNumber Of Participants With Treatment-emergent Adverse Events, Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single And Multiple SC Doses Of ALXN1830, Maximum Observed Plasma Concentration (Cmax) Of Single And Multiple SC Doses Of ALXN1830, (and 2 more...)
- 4y agoALXNA Prospective Sub-Study of the Global Hypophosphatasia Registry - NCT05234567ClinicalTrials.govOccurrence Of Immune-mediated Loss Of Effectiveness According To The Treating Physician, Occurrence Of Immune-mediated Serious Adverse Events
- 4y agoALXNStudy of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis - NCT05218096ClinicalTrials.govProportion Of Participants With A Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score Reduction Of ≥ 2 Points In Any 4 Consecutive Weeks During The First 8 Weeks And Who Did Not Receive Rescue Therapy, Change From Baseline In Quantitative Myasthenia Gravis (QMG) Total Score At Week 8, Proportion Of Participants Meeting Prespecified Threshold In The QMG Total Score At Week 8, (and 12 ...
- 4y agoALXNDrug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants - NCT05202145ClinicalTrials.govPart 1 Cyclosporine: Area Under The Concentration-Time Curve From Time Zero To The 12-hour Time Point (AUC0-12) Following Multiple Dose Cyclosporine Alone Versus When Dosed In The Presence Of Steady-state ALXN2050, Part 1: ALXN2050 AUC0-12 Following Multiple Dose ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Cyclosporine, Part 1: Cyclosporine Maximum Observed Concentr ...
- 5y agoALXNA Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults - NCT05109390ClinicalTrials.govPart 1: Cyclosporine Maximum Observed Concentration (Cmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan, Part 1: Cyclosporine Time To Reach The Maximum Observed Concentration (Tmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan, Part 1: Cyclosporine Area Under The Concentration-time Curve From Time 0 Extrapola ...
- 5y agoALXNStudy of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN) - NCT05097989ClinicalTrials.govBoth Cohorts: Percentage Change In Proteinuria From Baseline To Week 26, Both Cohorts: Percentage Change In Proteinuria From Baseline To Week 50, Both Cohorts: Participants Achieving > 30% And > 50% Reduction In Proteinuria At Week 26 And Week 50 Compared To Baseline, (and 13 more...)
- 5y agoALXNA Study of the Cardiac Effects of Danicopan in Healthy Adults - NCT05016206ClinicalTrials.govPlacebo-corrected Change From Baseline In QTc Intervals (ddQTc) For Danicopan, Change From Baseline In Heart Rate (HR) For Danicopan, Change From Baseline In QT Interval For Danicopan, (and 9 more...)
- 5y agoALXNRavulizumab Versus Placebo in Adult Participants With Dermatomyositis - NCT04999020ClinicalTrials.govPart A: Proportion Of Participants With A ≥ 20-point Improvement Response On International Myositis Assessment And Clinical Studies-Total Improvement Score (IMACS-TIS) (TIS20) At Week 26 Of The Randomized Controlled Period, Part B: Proportion Of Participants With A ≥ 20-point Improvement Response On TIS20 At Week 50, Part A: Mean TIS At Week 26, (and 27 more...)
- 5y agoALXNStudy of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis - NCT04982289ClinicalTrials.govAdverse Events (AEs) And Serious Adverse Events (SAEs) Up To Week 24, AEs And SAEs Up To Week 82, Change From Baseline In Serum Total Immunoglobulin G (IgG), (and 9 more...)
- 5y agoALXNStudy of ALXN1850 in Participants With Hypophosphatasia (HPP) - NCT04980248ClinicalTrials.govIncidence Of Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events, Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single IV And Multiple SC Doses Of ALXN1850, Maximum Observed Plasma Concentration (Cmax) Of Single IV And Multiple SC Doses Of ALXN1850, (and 4 more...)
- 5y agoNKTRLBTSLABNTX+3Moderna Surges as S&P 500 Inclusion Boosts Vaccine MakerBloomberg
- 5y agoDIDI22UA-DEMRNAALXN+14Stocks making the biggest moves premarket: Moderna, Didi, BioNTech, AMC and othersCNBCThese are the stocks posting the largest moves before the bell.
- 5y agoALXNAZNMRNASPGIModerna Set to Join S&P 500PR NewswireNEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexio
- 5y agoALXNTSLAMRNAModerna Climbs as S&P 500 Set to Welcome Covid Vaccine MakerBloomberg
- 5y agoALXNAlexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)Business Wire– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Al